Sign up to SCR Digest, our FREE weekly newsletter, and receive our Notes emailed directly to you. Click here.

CTSO: Strong Cash Position & Growing Database


By M. Marin



58% Y/Y Growth, Including CytoSorb For COVID-19 Treatment, Drives Need To Expand Production

Cytosorbents (NASDAQ:CTSO) raised nearly $57.5 million in an over-subscribed equity offering at $9.50 per share, with funds earmarked to expand manufacturing capacity, fund clinical studies to advance CTSO’s product portfolio and expand the direct sales team. We estimate pro forma cash at over $85 million.

CTSO also has been extremely successful at minimizing its cash burn for R&D by leveraging grants and government awards. CTSO continues to advance HemoDefend and recently received a U.S. Army research award for up to $4.4 million and a Defense Health Agency Small Business Technology Transfer (STTR) contract for up to $2.9 million for HemoDefend.

The company also pre-announced key metrics from 2Q20 results. Revenue reached a record $9.8 million in 2Q20, up 58% y/y despite hospital mandates to delay many cardiac surgeries. Strong demand, including for COVID-19 treatment, drove delivery of more than 98,000 CytoSorb treatments in the last 12 months, up from 67,000 in the prior year, a greater than 46% advance. This equates to sales of roughly $30 million over the past 12 months and illustrates that sales of CytoSorb have increased at a CAGR of roughly 56% in the past five years. CTSO plans to report 2Q20 results on August 4.

Database of Evidence Supporting Utility of CytoSorb Continues to Grow

We believe CytoSorb treatment for COVID-19 and cytokine storm continues to produce data that adds to the database of evidence supporting the utility of CytoSorb. As this database continues to grow, we believe it will be a key catalyst in driving awareness, adoption and utilization of CytoSorb.

SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. 

DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks provides and Zacks receives quarterly payments totaling a maximum fee of $40,000 annually for these services. Full Disclaimer HERE.

User ID:
Remember my ID: